Supportive Therapy Play a Vital Role in the Treatment of Leukemia: A Review

Authors

  • Prabhjot Bains
  • Madan L. Kaushik

Abstract

Leukemia is a major burden worldwide. The anomalous production of white blood cells (WBC) is responsible for producing leukemia; these cells are also known as blasts. A study indicated that thousands of patients are detected every year with leukemia risk worldwide. The risk factor including chemical exposure, ionizing radiations, cigarette smoking is the major causes for developing leukemia. There are four types of leukemia and number of genes involved are RUNX1, CEBPA, ETV6, TERT, SH2B3, PAX5, SMAD2, CDK9, MEN1, HDAC1, and LCK. Alteration in gene response and signaling pathway leads to the formation of blasts. Mutation plays a vital role in MAP kinase process involved in leukemogenesis. Leukemia is diagnosed by complete blood count, bone marrow tests, chromosome testing, and imaging testing. Therapies have been used for leukemia such as targeted therapy, radiotherapy, chemotherapy, IFN therapy, stem cell transplantation, watchful waiting and supportive therapy. Leukemia is treated with any of these therapies but there is a still need of supportive therapy which plays a crucial role in the management of complications occurred during leukemia treatment. Marketed drugs and newly approved drug by the Food and Drug Administration (FDA) prevent leukemia and their serious adverse effect. Supportive therapy plays a vital role to enhance the recovery from leukemia.

 

Keywords: Leukemia, white blood cells (WBC), blasts, mutation, supportive therapy

Cite this Article

Bains P, Kaushik ML. Supportive Therapy Play a Vital Role in the Treatment of Leukemia: A Review. Research & Reviews: A Journal of Pharmacology. 2018; 8(3): 1–8p.

Downloads

Published

2019-01-02

Issue

Vol. 8 No. 3 (2018)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.